Myeloproliferative Neoplasms News

Professor Geoffrey Hill has been appointed director of hematopoietic stem cell transplantation at Fred Hutchinson Cancer Research Center.

HemOnc Today honored its inaugural class of Next Gen Innovators during the ASH Annual Meeting and Exposition.

Ruxolitinib did not demonstrate superiority over best available second-line therapy among patients with high-risk essential thrombocythemia, according to result of the randomized, phase 2 MAJIC study published in Blood.

Hypomethylating agents used at a low dose appeared effective and safe for patients with lower-risk myelodysplastic syndrome, according to results of a randomized phase 2 clinical trial.

The top stories in hematology and oncology this year included articles on study results published in peer-reviewed journals, FDA approvals and practice-changing data presented at scientific meetings, as well as articles that featured interviews with leading researchers and expert opinions on approaches to patient care.

ATLANTA — Patients who received autologous and allogeneic hematopoietic stem cell transplantation in their homes maintained their quality of life and had low rates of infectious complications, according to a small, phase 1 study presented at the ASH Annual Meeting and Exposition.

ATLANTA — Although adults aged 65 to 74 years appeared adequately represented in hematologic malignancy clinical trials between 2005 and 2015, those aged 75 years or older were disproportionately underrepresented, according to a retrospective analysis conducted by the FDA and presented at the ASH Annual Meeting and Exposition.

ATLANTA — BLU-285 appeared active and safe among patients with advanced systemic mastocytosis, according to phase 1 data presented during the plenary session of the ASH Annual Meeting and Exposition.

ATLANTA — Immunosuppressive therapy helped nearly 40% of patients with myelodysplastic syndrome achieve transfusion independence, according to study results presented at ASH Annual Meeting and Exposition.

SAN ANTONIO — Creating a dynamic regulatory environment requires the FDA is responsive to societal demands in conjunction with emerging scientific advances, according to Richard Pazdur, MD.